Piramal Pharma Limited CC-Dec23.pdf · 2024-01-31
To start with, I wanted a bit more granularity on the demand front. I understand that right now biotech funding environment is weak, but are you seeing any kind of traction in the RF Ps or enquiries? And secondly, you said you you're seeing good traction on the commercial molecules. So, does that give a more longer -term visibility now with more commercial mole cules under execution, so some color on that?
So, related to that, I understand it's early days yet, but recently there was a proposed BIOSECURE Act which looks dealing with China. So , what are your initial thoughts on that? Would it stand to benefit Piramal's business?